Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Chugai Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Chugai Pharmaceutical kazanç ve gelirin sırasıyla yıllık 6.5% ve 4.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 6.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 17.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

6.5%

Kazanç büyüme oranı

6.5%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	14.0%
Gelir büyüme oranı	4.5%
Gelecekteki özkaynak getirisi	17.3%
Analist kapsamı	Good
Son güncelleme	23 Sep 2024

Gelecekteki son büyüme güncellemeleri

Results: Chugai Pharmaceutical Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Jul 30

Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Apr 26

Recent updates

Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00

Sep 24

Results: Chugai Pharmaceutical Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Jul 30

Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Trailing The Market But Its Shares Aren't

Jun 17

Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year

May 04

We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings

May 01

Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Apr 26

Chugai Pharmaceutical Co., Ltd. (TSE:4519) Investors Are Less Pessimistic Than Expected

Mar 01

Kazanç ve Gelir Büyüme Tahminleri

TSE:4519 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (JPY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1,208,180	413,914	368,560	425,886	13
12/31/2025	1,151,434	382,910	345,315	407,900	15
12/31/2024	1,116,076	364,125	361,330	406,758	15
6/30/2024	1,084,570	355,041	265,465	327,068	N/A
3/31/2024	1,036,076	326,373	323,991	383,090	N/A
12/31/2023	1,111,367	325,472	350,827	409,925	N/A
9/30/2023	1,276,051	336,745	205,825	258,712	N/A
6/30/2023	1,243,437	326,969	200,169	252,605	N/A
3/31/2023	1,211,632	316,154	252,376	299,319	N/A
12/31/2022	1,259,946	374,429	172,873	244,112	N/A
9/30/2022	1,143,716	370,791	298,989	366,072	N/A
6/30/2022	1,205,696	389,011	339,236	422,551	N/A
3/31/2022	1,191,496	387,359	227,919	305,626	N/A
12/31/2021	999,759	302,995	206,760	279,626	N/A
9/30/2021	887,919	256,462	180,866	256,890	N/A
6/30/2021	809,055	230,577	194,361	252,664	N/A
3/31/2021	776,339	210,611	165,601	246,567	N/A
12/31/2020	786,946	214,733	143,646	205,035	N/A
9/30/2020	753,853	202,590	127,482	211,422	N/A
6/30/2020	734,019	190,599	108,080	196,718	N/A
3/31/2020	711,320	174,062	116,245	178,610	N/A
12/31/2019	686,184	157,560	145,464	206,641	N/A
9/30/2019	662,198	139,543	83,362	160,274	N/A
6/30/2019	614,949	113,070	43,280	118,955	N/A
3/31/2019	586,648	99,631	23,827	101,309	N/A
12/31/2018	579,787	92,488	41,403	119,074	N/A
9/30/2018	572,994	85,857	91,950	125,700	N/A
6/30/2018	566,548	85,285	84,103	120,997	N/A
3/31/2018	556,159	82,101	N/A	127,695	N/A
12/31/2017	534,199	72,713	N/A	107,623	N/A
9/30/2017	517,908	67,704	N/A	63,732	N/A
6/30/2017	497,023	58,143	N/A	67,355	N/A
3/31/2017	497,354	57,592	N/A	49,230	N/A
12/31/2016	491,780	53,592	N/A	38,787	N/A
9/30/2016	492,584	56,562	N/A	40,808	N/A
6/30/2016	506,192	62,537	N/A	39,670	N/A
3/31/2016	501,649	61,043	N/A	49,913	N/A
12/31/2015	498,839	61,125	N/A	62,918	N/A
9/30/2015	495,455	58,897	N/A	75,502	N/A
6/30/2015	479,265	52,220	N/A	50,719	N/A
3/31/2015	454,147	46,786	N/A	54,919	N/A
12/31/2014	461,109	50,980	N/A	37,034	N/A
9/30/2014	450,545	52,461	N/A	38,017	N/A
6/30/2014	444,658	55,044	N/A	60,556	N/A
3/31/2014	457,281	60,774	N/A	54,886	N/A
12/31/2013	423,652	50,895	N/A	53,521	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 4519 'nin tahmini kazanç büyümesi (yıllık 6.5% ) tasarruf oranının ( 0.3% ) üzerindedir.

Kazançlar ve Piyasa: 4519 şirketinin kazançlarının (yıllık 6.5% ) JP pazarından (yıllık 8.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 4519 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 4519 şirketinin gelirinin (yıllık 4.5% ) JP pazarından (yıllık 4.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 4519 şirketinin gelirinin (yıllık 4.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 4519 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 17.3 %).

Chugai Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Results: Chugai Pharmaceutical Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Price target increased by 7.5% to JP¥5,780

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Nine Months and Financial Year Ending December 31, 2023

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Financial Year 2023

Recent updates

Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00

Now 20% overvalued after recent price rise

Results: Chugai Pharmaceutical Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Chugai Pharmaceutical (TSE:4519) Is Due To Pay A Dividend Of ¥41.00

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Estimating The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)

Upcoming dividend of JP¥41.00 per share

Chugai Pharmaceutical (TSE:4519) Is Increasing Its Dividend To ¥41.00

Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Trailing The Market But Its Shares Aren't

Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year

We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings

Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Final dividend of JP¥41.00 announced

Chugai Pharmaceutical Co., Ltd. (TSE:4519) Investors Are Less Pessimistic Than Expected

Price target increased by 7.5% to JP¥5,780

Full year 2023 earnings: EPS exceeds analyst expectations

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024

Upcoming dividend of JP¥40.00 per share at 1.5% yield

Chugai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Nine Months and Financial Year Ending December 31, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥40.00 per share at 1.9% yield

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Financial Year 2023

Chugai Pharmaceutical Co., Ltd. Approves Dividend Fiscal Year Ended December 31, 2022, Effective March 31, 2023

Now 20% undervalued after recent price drop

Upcoming dividend of JP¥38.00 per share

Now 21% undervalued

Less than half of directors are independent

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on Feb 02, 2023

Chugai Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Apr 27, 2023

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for Full Year of Year Ending December 31, 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Chugai Pharmaceutical Co., Ltd. to Report Q2, 2022 Results on Aug 21, 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for first Six Months and Full Year of Year Ending December 2022

Chugai Pharmaceutical Co., Ltd. to Report Nine Months, 2022 Results on Oct 24, 2022

Upcoming dividend of JP¥38.00 per share

Chugai Pharmaceutical Co., Ltd. to Report Q2, 2022 Results on Jul 21, 2022

Less than half of directors are independent

Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year 2022

Chugai Pharmaceutical Co., Ltd. to Report Q1, 2022 Results on Apr 25, 2022

Now 21% undervalued after recent price drop

Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 29, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Chugai Pharmaceutical Co., Ltd. Provides End of Fiscal Year Dividend Guidance for the Year Ending December 2022

Upcoming dividend of JP¥30.00 per share

Third quarter 2021 earnings released: EPS JP¥52.32 (vs JP¥36.58 in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥43.02 (vs JP¥30.89 in 2Q 2020)

Chugai Pharmaceutical Co., Ltd. Obtains Regulatory Approval from the Ministry of Health, Labour and Welfare for the Anti-SARS-CoV-2 Monoclonal Antibody RONAPREVE

Chugai Pharmaceutical Co., Ltd. Announces That Roche Has Been Granted Marketing Authorization from the European Commission

Upcoming dividend of JP¥30.00 per share

Dividend reduced to JP¥30.00

CHMP Recommends EU Approval of Chugai's Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder

Chugai Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Full Year Ending December 31, 2021

Chugai Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Oct 22, 2021

Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan

Chugai Pharmaceutical Co., Ltd. Announces Management Changes

Full year 2020 earnings released: EPS JP¥131 (vs JP¥95.95 in FY 2019)

Revenue beats expectations, earnings disappoint

Chugai Pharmaceutical Co., Ltd Announces Executive Changes

New 90-day high: JP¥5,894

New 90-day high: JP¥5,406